Aging: Epigenetic modifications

Mishra, Sarita; Raval, Mahima; Kachhawaha, Akanksha Singh; Tiwari, Budhi Sagar; Tiwari, Anjana

doi:10.1016/bs.pmbts.2023.02.002

Cited by 4 publications

(2 citation statements)

References 217 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…cardiovascular diseases, diabetes) (4–6). Metabolic disorders are often defined as conditions that affect the body’s conversion of food into energy and the ability to eliminate waste (7). Key factors contributing to the risk of metabolic disorders are the intake of an unhealthy diet, a sedentary lifestyle, and insufficient exercise, among others (7).…”

Section: Introductionmentioning

confidence: 99%

“…Nonpharmaceutical intervention efforts that target lifestyle factors are a promising approach to navigating metabolic disorders (7), and increasingly involve digital health technologies (DHTs)– which are defined by the Food and Drug Administration (FDA) as “computing platforms, connectivity, software, and sensors used for health care and related uses (8,9). Notably, DHTs may help older adults and caregivers manage aspects of metabolic health in day-to-day life (vs. in the clinic) and overcome barriers of more traditional health assessments (10), e.g., by reducing costs associated with in-person visits for patients and reducing burden for healthcare professionals, enhanced experience for patients, as well as improved mental health for healthcare professionals (11).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Digital Health Technologies for Metabolic Disorders in Older Adults: A Scoping Review Protocol

Huynh,

Fleisch,

Brändle

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: Metabolic disorders (type 2 diabetes, insulin resistance, hyperglycemia, obesity, hyperlipidemia, hypertension, nonalcoholic fatty liver disease, and metabolic syndrome) are leading causes of mortality and disability worldwide and disproportionately affect older adults relative to those younger. Digital health technologies (DHTs), such as patient monitoring, digital diagnostics, and digital therapeutics, emerge as promising tools for navigating health in day-to-day life. However, their role in targeting metabolic disorders, particularly among a key demographic of older adults, is not yet fully understood. Thus, this work aims to scope the use of DHTs in managing metabolic health disorders among older adults. Methods and Analysis: We will conduct a scoping review following the recommended framework by Arksey and O'Malley (1). Our search will focus on three primary concepts: metabolic disorders, DHTs, and older adults. We plan to search five online databases (Cochrane, Embase, PubMed, Scopus, and Web of Science) to identify original research articles published between January 2014 and January 2024. Two reviewers will independently screen articles for inclusion based on predetermined criteria, and a separate reviewer will resolve conflicts. Data will be extracted using a standardized form, and the findings will be synthesized and reported qualitatively and quantitatively. Ethics and dissemination. No ethics approval is required for this protocol and scoping review, as data will be used only from published studies with appropriate ethics approval. Results will be disseminated in a peer-reviewed publication. This protocol has been preregistered on OSF Repository at: https://osf.io/9s8fm.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Digital Health Technologies for Metabolic Disorders in Older Adults: A Scoping Review Protocol

Huynh,

Fleisch,

Brändle

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

RNA modification in normal hematopoiesis and hematologic malignancies

Chen,

Yuan,

Zhou

et al. 2024

MedComm

View full text Add to dashboard Cite

N6‐methyladenosine (m6A) is the most abundant RNA modification in eukaryotic cells. Previous studies have shown that m6A plays a critical role under both normal physiological and pathological conditions. Hematopoiesis and differentiation are highly regulated processes, and recent studies on m6A mRNA methylation have revealed how this modification controls cell fate in both normal and malignant hematopoietic states. However, despite these insights, a comprehensive understanding of its complex roles between normal hematopoietic development and malignant hematopoietic diseases remains elusive. This review first provides an overview of the components and biological functions of m6A modification regulators. Additionally, it highlights the origin, differentiation process, biological characteristics, and regulatory mechanisms of hematopoietic stem cells, as well as the features, immune properties, and self‐renewal pathways of leukemia stem cells. Last, the article systematically reviews the latest research advancements on the roles and mechanisms of m6A regulatory factors in normal hematopoiesis and related malignant diseases. More importantly, this review explores how targeting m6A regulators and various signaling pathways could effectively intervene in the development of leukemia, providing new insights and potential therapeutic targets. Targeting m6A modification may hold promise for achieving more precise and effective leukemia treatments.

show abstract